July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A Multicentre Double-masked Randomised Controlled Non-Inferiority Trial comparing clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion [LEAVO]: Baseline patient sociodemographic and ocular characteristics.
Author Affiliations & Notes
  • Philip G Hykin
    Moorfields Eye Hospital, London, ENGLAND, United Kingdom
  • Joana Vasconcelas
    Imperial College, London, United Kingdom
  • Toby Prevost
    Imperial College, London, United Kingdom
  • Sobha Sivaprasad
    Moorfields Eye Hospital, London, ENGLAND, United Kingdom
  • Barry Hounsome
    Kings College CTU, London, United Kingdom
  • Usha Chakravarthy
    Queen's University Belfast, Belfast, United Kingdom
  • Simon Harding
    University of Liverpool, Liverpool, United Kingdom
  • Andrew Lotery
    University of Southampton, Southampton, United Kingdom
  • Yit C. Yang
    Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
  • Piyali Sen
    Moorfields Eye Hospital, London, ENGLAND, United Kingdom
  • Jayashree Ramu
    Moorfields Eye Hospital, London, ENGLAND, United Kingdom
  • Luke Nicholson
    Moorfields Eye Hospital, London, ENGLAND, United Kingdom
  • Tunde Peto
    Queen's University Belfast, Belfast, United Kingdom
  • Footnotes
    Commercial Relationships   Philip Hykin, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Novartis (F), Novartis (R); Joana Vasconcelas, None; Toby Prevost, None; Sobha Sivaprasad, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Boehringer Ingelheim (R), Heidelberg Engineering (R), Novartis (F), Novartis (R), Optos (R), Roche (R); Barry Hounsome, None; Usha Chakravarthy, None; Simon Harding, Genentech (R), Roche (R); Andrew Lotery, Bayer (R), Gyroscope Therapeutics (F), Gyroscope Therapeutics (I), Gyroscope Therapeutics (C), Roche (R); Yit Yang, Allergan (R), Bayer (R), Novartis (R); Piyali Sen, None; Jayashree Ramu, None; Luke Nicholson, None; Tunde Peto, Bayer (R), Novartis (R), Optos (R)
  • Footnotes
    Support  UK NIHR HTA Programme Grant 11/92/03
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2569. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Philip G Hykin, Joana Vasconcelas, Toby Prevost, Sobha Sivaprasad, Barry Hounsome, Usha Chakravarthy, Simon Harding, Andrew Lotery, Yit C. Yang, Piyali Sen, Jayashree Ramu, Luke Nicholson, Tunde Peto; A Multicentre Double-masked Randomised Controlled Non-Inferiority Trial comparing clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema due to Central Retinal Vein Occlusion [LEAVO]: Baseline patient sociodemographic and ocular characteristics.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2569.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There has been no direct comparison of the clinical and cost effectiveness of intravitreal therapy with ranibizumab, aflibercept and bevacizumab in macular oedema (MO) due to central retinal vein occlusion (CRVO) in a large randomised clinical trial. The baseline sociodemographic and ocular characteristics of patients enrolled in the LEAVO study are presented.

Methods : Patients (n=463) with MO due to CRVO, baseline BCVA of 19 to 78 letters were recruited in 44 UK Centres, randomised 1:1:1 to bevacizumab, aflibercept or ranibizumab and treated to 100 weeks with four mandated monthly anti-VEGF intravitreal injections followed by repeated injection if pre specified retreatment criteria were met. The primary outcome is change in BCVA from baseline to 100 weeks in all patients. Baseline age, gender, ethnicity, prior treatment, duration of CRVO, glaucoma history, study eye BCVA letter score , IOP, OCT mean central subfield thickness (CST) and macular volume are presented by masked subgroup.

Results : Key baseline sociodemographic and ocular characteristic data are presented in Table 1. (subject to minor change prior to datalock). In addition, 94% of patients in subgroup A, 93% in B and 93% in C were white, 5% in A and B and 6% in C were asian. 6% in subgroup A, 8% in B and 9% in C had pre existing glaucoma and IOP mmHg (SD) was 15.8(3.3), 16.3(3.7) and 16.6(5.1) respectively. OCT mean (SD) total volume (mm3) was 12.0 (3.0) in subgroup A, 12.8(3.0) in B and 12.4(3.4) in C.

Conclusions : The data indicate that baseline patient demographics and ocular characteristics are well balanced across subgroups, last patient last visit is 2018 with primary outcome data due early 2019.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

CST= central subfield thickness, BCVA= best corrected visual acuity (refracted).

CST= central subfield thickness, BCVA= best corrected visual acuity (refracted).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×